Therefore, the combination of targeting CD16a, EGFR and PD-L1 could provide significant clinical benefit also in view of the recently reported finding that tumor-specificity can be elevated by simultaneous targeting EGFR and PD-L1 by a bispecific antibody (27). The gene discussed is EGFR; the disease is neoplasm.